Cardiometabolic Outcomes with Dapagliflozin After Myocardial Infarction by Baseline Ejection Fraction: DAPA-MI
Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, although there was no impact on the composite of cardiovascular death or hospitalization for HF.
Authors
- Anna Maria Langkilde (ORCID: https://orcid.org/0000-0002-1696-9356)
- David J. Austin (ORCID: https://orcid.org/0000-0003-4606-1055)
- Niclas Eriksson (ORCID: https://orcid.org/0000-0002-2152-4343)
- Julian Strange (ORCID: https://orcid.org/0000-0003-0476-0886)
- John Eric Deanfield (ORCID: https://orcid.org/0000-0001-8806-6052)
- Robert F. Storey (ORCID: https://orcid.org/0000-0002-6677-6229)
- Wilhelm Ridderstråle (ORCID: https://orcid.org/0000-0002-7944-7993)
- Annica Ravn‐Fischer (ORCID: https://orcid.org/0000-0003-2585-1592)
- Ehsan Parvaresh Rizi (ORCID: https://orcid.org/0000-0002-2513-8829)
- Mark de Belder (ORCID: https://orcid.org/0000-0003-2690-8319)
- Sofia Sederholm Lawesson (ORCID: https://orcid.org/0000-0002-4776-0870)
- Daniel A. Jones (ORCID: https://orcid.org/0000-0003-1441-0417)
- Peter A. Johansson (ORCID: https://orcid.org/0000-0001-7015-5452)
- Darren K. McGuire (ORCID: https://orcid.org/0000-0002-6412-7989)
- Karolina Szummer (ORCID: https://orcid.org/0000-0002-0994-8135)
- Stefan Karl James (ORCID: https://orcid.org/0000-0003-4413-9736)
- David Erlinge (ORCID: https://orcid.org/0000-0003-3042-5766)
- Monér Alchay (ORCID: https://orcid.org/0009-0009-8607-9293)
- Nikunj Shah
Institutions
- Linköping University (SE)
- Uppsala University (SE)
- Parkland Health & Hospital System (US)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- Queen Mary University of London (GB)
- Lund University (SE)
- University Hospitals Bristol NHS Foundation Trust (GB)
- Sahlgrenska University Hospital (SE)
- Queen Alexandra Hospital (GB)
- Karolinska Institutet (SE)
- South Tees Hospitals NHS Foundation Trust (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- AstraZeneca (Finland) (FI)
- Weston Area Health NHS Trust (GB)
- Norra Älvsborgs Länssjukhus (SE)
- AstraZeneca (Spain) (ES)
- William Harvey Research Institute (GB)
- Linköping University Hospital (SE)
- NIHR Research Delivery Network (GB)
- University College London (GB)
- Newcastle University (GB)
- The University of Texas Southwestern Medical Center (US)
- University of Gothenburg (SE)
- University of Sheffield (GB)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1002/ehf2.15420
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca